Brokerages Set Genmab A/S (NASDAQ:GMAB) Target Price at $45.20

Genmab A/S (NASDAQ:GMAB) has received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $45.20.

GMAB has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the business. Brandywine Global Investment Management LLC purchased a new position in Genmab A/S in the 4th quarter worth approximately $33,804,000. JPMorgan Chase & Co. lifted its position in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock worth $8,507,000 after buying an additional 394,670 shares in the last quarter. Trexquant Investment LP lifted its position in Genmab A/S by 495.1% during the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock worth $7,929,000 after buying an additional 316,089 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new stake in Genmab A/S in the 4th quarter valued at $3,692,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

GMAB opened at $19.69 on Friday. The company has a fifty day moving average of $20.72 and a two-hundred day moving average of $23.24. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, equities research analysts forecast that Genmab A/S will post 1.25 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.